Bafna Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing of pharmaceutical formulations. The Company exports its products to the Europe, the United Kingdom, Australia, Sri Lanka, Africa, and Commonwealth countries.

Employees

339

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
28/10/26	₹451.60	+2.00%	11,610
27/10/26	₹442.75	+1.99%	4,915
26/10/26	₹434.10	-2.00%	9,309
23/10/26	₹442.95	-1.99%	1,422
22/10/26	₹451.95	-2.00%	4,534

End-of-day quote NSE India S.E.

More quotes

End-of-day quote NSE India S.E. 28/10/2026			5-day change	1st Jan Change
451.60 ^INR	+2.00%		-4.03%	+199.63%

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI

Market Cap	10.68B 112M 101M 93.05M 84.27M 157M 159M 1.11B 443M 5.59B 421M 412M 17.75B	P/E 2025	42.6x	P/E 2026	23.3x
Enterprise Value	11.04B 116M 104M 96.13M 87.06M 163M 165M 1.15B 458M 5.78B 435M 426M 18.34B	EV / Sales 2025	1.38x	EV / Sales 2026	1.95x
Free-Float	10.3%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
NSE India S.E.	BAFNAPH	End-of-day quote
Bombay S.E.	BAFNAPH	Delayed

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI
05-29	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
19/09/25	Bafna Pharmaceuticals Limited Appoints Navin Kumar as Non-Executive, Independent Director	CI
12/08/25	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
12/08/25	Bafna Pharmaceuticals Limited Approves Reconstitution of Nomination & Remuneration Committee, Effective August 12, 2025	CI
24/06/25	Bafna Pharmaceuticals Limited Announces Board and Committee Changes, Effective from June 24, 2025	CI
26/05/25	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	CI
01/04/25	Bafna Pharmaceuticals Limited Announces Resignation of Krishna Yeachuri as Independent Director and Cessation as Chairman of Nomination & Remuneration Committee, Effective March 31, 2025	CI
06/02/25	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
11/11/24	Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI
13/08/24	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI

Bafna Pharmaceuticals Limited Stock

Stocks

BAFNAPH

INE878I01022

Pharmaceuticals

Valuation: Bafna Pharmaceuticals Limited

Chart: Bafna Pharmaceuticals Limited

Latest news: Bafna Pharmaceuticals Limited

Quotes and Performance

Price Extremes

Managers and Directors: Bafna Pharmaceuticals Limited

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+2.00%
1 week	-4.03%
Current month	+21.61%
1 month	+29.01%
3 months	+85.91%
6 months	+238.20%
Current year	+199.63%

1 week	434.1	451.95
1 month	364.15	479.95
Current year	94.77	479.95
1 year	94.77	479.95
3 years	69	479.95
5 years	69	479.95
10 years	4.4	479.95

Manager	Title	Age	Since
Bansilal Mahaveer C. Bafna CEO	Chief Executive Officer	64	01/01/1981
Melagiri Sridhar DFI	Director of Finance/CFO	-	-
A. Mohanachandran CMP	Compliance Officer	-	29/05/2024

Director	Title	Age	Since
Hemalatha Shanmugam BRD	Director/Board Member	51	10/09/2020
Akilapriya C. Raju BRD	Director/Board Member	-	10/09/2020
Chitra Ravichandran CHM	Chairman	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAFNA PHARMACEUTICALS LIMITED	+2.00%	-4.03%	+240.32%	+443.77%	110M
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+129.96%	1,143B
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+86.15%	647B
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+105.85%	506B
ROCHE HOLDING AG	-0.05%	+1.73%	+52.74%	+67.74%	384B
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.06%	350B
NOVARTIS AG	+0.34%	+1.84%	+30.70%	+54.27%	293B
ASTRAZENECA PLC	-0.45%	+1.19%	+2.89%	+26.08%	265B
AMGEN INC.	+0.87%	+3.08%	+54.69%	+72.74%	242B
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+107.78%	197B
Average	+0.34%	+0.75%	+60.61%	+113.14%	402.76B
Weighted average by Cap.	+0.25%	+0.71%	+44.50%	+89.03%

	2025	2026
Net sales	1.46B 15.31M 13.74M 12.7M 11.51M 21.49M 21.75M 152M 60.5M 763M 57.47M 56.26M 2.42B	1.51B 15.81M 14.19M 13.12M 11.88M 22.2M 22.46M 157M 62.47M 788M 59.35M 58.09M 2.5B
Net income	41.52M 436K 391K 362K 328K 612K 619K 4.32M 1.72M 21.73M 1.64M 1.6M 68.98M	111M 1.17M 1.05M 967K 876K 1.64M 1.66M 11.56M 4.6M 58.08M 4.37M 4.28M 184M
Net Debt	248M 2.6M 2.33M 2.16M 1.95M 3.65M 3.69M 25.79M 10.27M 130M 9.76M 9.55M 411M	354M 3.72M 3.34M 3.08M 2.79M 5.22M 5.28M 36.87M 14.69M 185M 13.95M 13.66M 588M